Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
869 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Carcinoma, Bronchogenic" (869 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
3 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
4 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
Intervention:
5 Recruiting Safety Study of MGA271 in Refractory Cancer
Conditions: Prostate Cancer;   Melanoma;   Renal Cell Carcinoma;   Triple-negative Breast Cancer;   Head and Neck Cancer;   Bladder Cancer;   Non-small Cell Lung Cancer
Intervention: Biological: MGA271
6 Unknown  Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer
Condition: Local Advanced Non-Small Cell Lung Cancer
Intervention: Other: Concurrent Pemetrexed, Cisplatin and Radiotherapy
7 Unknown  Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)
Condition: Small Cell Lung Cancer
Intervention:
8 Recruiting Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Conditions: HIV Infection;   Recurrent Anal Cancer;   Recurrent Breast Cancer;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Anal Cancer;   Stage IV Breast Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: carboplatin;   Drug: paclitaxel
9 Unknown  Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
Conditions: Toxicity;   Non-small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Pemetrexed;   Drug: Cisplatin or carboplatin
10 Recruiting Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941;   Drug: Placebo;   Drug: bevacizumab;   Drug: carboplatin;   Drug: paclitaxel
11 Recruiting Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Afatinib
12 Recruiting Validation of the MiCK Assay
Condition: Mesothelioma, Small Cell Lung Cancer, NSCLC
Intervention:
13 Not yet recruiting Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
Conditions: Non-small Cell Lung Cancer Metastatic;   EGFR Activating Mutation
Interventions: Drug: Gefitinib;   Drug: gemcitabine;   Drug: carboplatin
14 Recruiting Oligometastatic Disease
Condition: Lung Cancer
Interventions: Other: No LCT;   Other: LCT
15 Recruiting Systemic Treatment of Resistant Metastatic Disease
Conditions: Non-small Cell Lung Cancer;   Castrate-resistant Prostate Cancer;   Melanoma;   Bladder Cancer
Intervention: Biological: CVA21
16 Recruiting Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf
Condition: Non Small Cells Lung Cancer
Intervention:
17 Unknown  Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed;   Drug: pemetrexed and erlotinib
18 Recruiting Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Condition: Non Small Cell Lung Cancer
Intervention: Drug: BKM120 and Erlotinib
19 Recruiting A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Condition: ALK Positive Non Small Cell Lung Cancer
Intervention: Drug: PF-06463922
20 Unknown  Study for Patients With Non Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Vinorelbine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years